XML 92 R51.htm IDEA: XBRL DOCUMENT v3.25.0.1
Acquisitions, Divestitures, Research Collaborations and Licensing Agreements - Narrative (Details)
$ in Millions
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 02, 2021
Dec. 31, 2024
USD ($)
jurisdiction
Sep. 30, 2024
USD ($)
Jul. 31, 2024
USD ($)
candidate
aqua_facility
Mar. 31, 2024
USD ($)
Jun. 30, 2023
USD ($)
Jan. 31, 2023
USD ($)
Oct. 31, 2022
USD ($)
Aug. 31, 2022
USD ($)
Jul. 31, 2022
USD ($)
May 31, 2022
USD ($)
Mar. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
jurisdiction
Dec. 31, 2025
USD ($)
Dec. 31, 2024
USD ($)
jurisdiction
Dec. 31, 2023
USD ($)
Dec. 31, 2022
USD ($)
Apr. 30, 2024
candidate
Oct. 31, 2023
USD ($)
antibodyDrugConjugate
candidate
Feb. 28, 2023
USD ($)
candidate
Business Acquisition [Line Items]                                        
Research and development                             $ 17,938 $ 30,531 $ 13,548      
Sales                             64,168 60,115 59,283      
Cost of sales                             15,193 16,126 17,411      
Other current assets   $ 8,706                     $ 8,706   8,706 8,368        
Accrued and other current liabilities   15,694                     15,694   15,694 15,766        
Forecast | Subsequent Event                                        
Business Acquisition [Line Items]                                        
Contingent consideration                       $ 440                
Royalty Pharma                                        
Business Acquisition [Line Items]                                        
Compensation earned on arragement               $ 50                        
Related Party                                        
Business Acquisition [Line Items]                                        
Other current assets   330                     330   330 632        
Accrued and other current liabilities   $ 113                     $ 113   113 598        
Manufacturing and supply agreements | Related Party                                        
Business Acquisition [Line Items]                                        
Sales                             392 394 383      
Cost of sales                             $ 390 422 404      
Minimum | Manufacturing and supply agreements | Related Party                                        
Business Acquisition [Line Items]                                        
Period of continuing involvement after disposal 4 years                                      
Maximum | Manufacturing and supply agreements | Related Party                                        
Business Acquisition [Line Items]                                        
Period of continuing involvement after disposal 10 years                                      
Discontinued Operations, Disposed of by Means Other than Sale, Spinoff | Organon & Co.                                        
Business Acquisition [Line Items]                                        
Number of jurisdictions under interim operating agreement | jurisdiction   1                     1   1          
Orion                                        
Business Acquisition [Line Items]                                        
Eligible future contingent development-related payments (up to)       $ 30                                
Aggregate, regulatory milestones payments, maximum       625                                
Sales milestone payments       $ 975                                
Orion | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement                                        
Business Acquisition [Line Items]                                        
Upfront payment made to collaborative partner                   $ 290                    
Daiichi Sankyo | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement                                        
Business Acquisition [Line Items]                                        
Research and development                             $ 351 5,549        
Number of antibody drug conjugates obtained right and obligations | antibodyDrugConjugate                                     3  
Accrued and other current liabilities   $ 817                     $ 817   817 800        
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement                                        
Business Acquisition [Line Items]                                        
Eligible future contingent development-related payments (up to)                                     $ 540  
Aggregate, regulatory milestones payments, maximum                                     1,500  
Sales milestone payments                     $ 780               $ 3,100  
Number of antibody drug conjugates | candidate                                       7
Upfront payment made to collaborative partner                                       $ 175
Number of antibody drug conjugates terminated | candidate                                   1 2  
Number of exercised license option antibody drug conjugates | candidate       1                                
Number of licensed antibody drug conjugates | candidate       3                                
Number of unexercised license option antibody drug conjugates | candidate       1                                
Payment resulting from the license option exercise       $ 38                                
Stock investment in counterparty             $ 100                          
Option payment made to collaborative partner                     30                  
Milestone payment to be made to a collaborative partner                               25        
Contingent developmental milestone payments                             90          
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement | First Commercial Sale Milestones                                        
Business Acquisition [Line Items]                                        
Sales milestone payments                     $ 290                  
Orna Therapeutics | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement                                        
Business Acquisition [Line Items]                                        
Eligible future contingent development-related payments (up to)                 $ 440                      
Aggregate, regulatory milestones payments, maximum                 675                      
Sales milestone payments                 2,400                      
Preferred stock investment in counterparty                                 $ 100      
Upfront payment made to collaborative partner                 $ 150                      
Elanco Animal Health Incorporated Aqua Business                                        
Business Acquisition [Line Items]                                        
Cash paid for acquisition of business       $ 1,300                                
Aqua manufacturing facilities | aqua_facility       2                                
LM-299, LaNova Medicines Ltd                                        
Business Acquisition [Line Items]                                        
Consideration transferred, asset acquisition   588                                    
Maximum aggregate sales-based milestone payments   1,400                     1,400   1,400          
Future contingent developmental milestone payments (up to)   140                     140   140          
Future regulatory milestone payments (up to)   860                     860   860          
LM-299, LaNova Medicines Ltd | Forecast                                        
Business Acquisition [Line Items]                                        
Contingent consideration dependent upon technology transfer                           $ 300            
CN201, Curon Biopharmaceutical                                        
Business Acquisition [Line Items]                                        
Consideration transferred, asset acquisition     $ 700                                  
Future contingent developmental milestone payments (up to)     300                                  
Future regulatory milestone payments (up to)     300                                  
Research and development                             750          
CN201, Curon Biopharmaceutical | Third-Party                                        
Business Acquisition [Line Items]                                        
Aggregate contingent developmental, regulatory, and sales-based-related payments     $ 128                                  
Eyebiotech Limited                                        
Business Acquisition [Line Items]                                        
Consideration transferred, asset acquisition       $ 1,200                                
Maximum aggregate sales-based milestone payments       500                                
Future contingent developmental milestone payments (up to)       200                                
Future regulatory milestone payments (up to)       1,000                                
Research and development                             1,350          
Transaction costs       207                                
Developmental milestone payment triggered and paid                         100              
Net assets acquired       $ 21                                
Harpoon Therapeutics, Inc.                                        
Business Acquisition [Line Items]                                        
Consideration transferred, asset acquisition         $ 765                              
Research and development                             656          
Transaction costs         56                              
Net assets acquired         $ 165                              
Prometheus Biosciences, Inc.                                        
Business Acquisition [Line Items]                                        
Consideration transferred, asset acquisition           $ 11,000                            
Research and development                               10,200        
Net assets acquired           877                            
Consideration transferred, to settle share-based equity awards           1,200                            
Consideration transferred, to settle equity awards, unvested           700                            
Cash recorded for asset acquisition           368                            
Investments recorded for asset acquisition           296                            
Deferred tax assets recorded for asset acquisition           218                            
Other net liabilities recorded for asset acquisition           $ 5                            
Imago BioSciences, Inc.                                        
Business Acquisition [Line Items]                                        
Consideration transferred, asset acquisition             1,350                          
Research and development                               $ 1,200        
Transaction costs             60                          
Net assets acquired             $ 219                          
HS-10535 Hansoh Pharma                                        
Business Acquisition [Line Items]                                        
Consideration transferred, asset acquisition   112                                    
Maximum aggregate sales-based milestone payments   1,470                     1,470   1,470          
Future contingent developmental milestone payments (up to)   115                     115   115          
Future regulatory milestone payments (up to)   $ 315                     $ 315   $ 315